Anti-PSMA CAR mRNA-LNP
PSMA (Prostate-specific membrane antigen) is a cell surface membrane protein with some enzymatic activity, but its true role is unknown. PSMA has been detected in prostate tissue, prostate cancer cells, and serum. PSMA levels are high in primary prostate cancer and metastatic disease, with more than 90% of the protein ubiquitously present in diseased tissue. PSMA levels found in men with prostate cancer were significantly higher than those found in healthy men or men with benign prostatic hyperplasia. PSMA also appears to be upregulated in patients receiving hormone deprivation therapy. However, concrete evidence has yet to establish an association between high levels of serum PSMA and susceptibility to aggressive disease. Indeed, several studies have observed reduced serum PSMA levels in patients with advanced disease. In addition, high levels of PSMA have been found in the serum of breast cancer patients. This product is designed as a tool for the delivery and expression of anti-PSMA CAR mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-PSMA CAR mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-PSMA CAR in this product is approximately 56 kD and consists of anti-PSMA scFv (single-chain variable fragment) linked to a second-generation CAR (chimeric antigen receptor) containing the CD8 hinge and transmembrane domain and 4-1BB and CD3ζ signaling domains. The full-length amino acid sequence of this anti-PSMA CAR mRNA-LNP product is available upon request.